<DOC>
	<DOCNO>NCT02186301</DOCNO>
	<brief_summary>The purpose study compare safety anti-tumor effect rociletinib erlotinib patient whose tumor specific EGFR mutation previously receive treatment advanced/metastatic EGFR mutate NSCLC . This study 'Randomized ' Study . This mean upon enter study , patient randomly assign dose either rociletinib twice day erlotinib day . Patients continue take either rociletinib erlotinib longer beneficial .</brief_summary>
	<brief_title>TIGER-1 : Safety Efficacy Study Rociletinib ( CO-1686 ) Erlotinib Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy</brief_title>
	<detailed_description>This randomize , Phase 2/3 study rociletinib versus erlotinib first-line treatment patient EGFR-mutant advanced/metastatic NSCLC whose tumor EGFR-activating mutation . The study consist Phase 2 Phase 3 part use enrollment criterion treatment assignment principle . Patients randomize 1:1 erlotinib rociletinib . The Phase 2 part open-label study . In Phase 3 part , sponsor blind efficacy safety result . The study consist screen phase establish study eligibility ( include tumor genotype ) document baseline measurement , treatment phase , patient receive either rociletinib BID erlotinib QD ascertain safety efficacy protocol-defined disease progression , follow-up phase , monitor survival status subsequent NCSLC cancer therapy . In Phase 2 part , patient initially randomize erlotinib may eligible participate optional crossover phase receive rociletinib demonstrate T790M resistance mutation radiographic progression erlotinib treatment among eligibility requirement . Patients eligible study must EGFR-mutated NSCLC treat EGFR-directed therapy.Treatment rociletinib erlotinib continuous . Each 28 day period treatment represent one cycle , dose initiated Cycle 1 Day 1 ( C1 D1 ) .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Histologically cytologically confirm metastatic unresectable locally advanced/metastatic NSCLC 2 . Documented evidence tumor activate EGFR mutation local test . Patients exon 20 insertion eligible exception patient document evidence exon 20 insertion A763_Y764insFQEA EGFR gene 3 . Have undergone biopsy surgical resection either primary metastatic tumor tissue within 60 day first day study treatment , C1D1 , tissue available send sponsor laboratory able undergo biopsy screen provide tissue sponsor laboratories 4 . Measureable disease accord RECIST Version 1.1 5 . Life expectancy least 3 month 6 . ECOG performance status 0 1 7 . Minimum age 18 year ( certain territory , minimum age requirement may higher ( e.g . 20 year Japan Taiwan ) 8 . Adequate hematological biological function , confirm defined laboratory value 9 . Written consent IRB/IECapproved Informed Consent Form ( ICF ) prior studyspecific evaluation 1 . Documented evidence exon 20 insertion activate mutation A763_Y764insFQEA EGFR gene 2 . Prior treatment cytotoxic chemotherapy advance NSCLC ; neoadjuvant/adjuvant chemotherapy permit least 6 month elapse end chemotherapy randomization 3 . Active second malignancy ; i.e. , patient know potentially fatal cancer present he/she may ( necessarily ) currently receive treatment 4 . Patients history malignancy completely treat , currently evidence cancer , permit enroll trial provide chemotherapy complete &gt; 6 month prior and/or bone marrow transplant &gt; 2 year prior first day study treatment 5 . Known preexist interstitial lung disease 6 . Brain metastases 7 . Treatment prohibit medication less equal 14 day prior first day study treatment 8 . Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication prior administration study drug 9 . Prior treatment EGFR TKIs ( e.g . erlotinib , gefitinib , neratinib , afatinib , AZD9291 , dacomitinib ) , rociletinib drug target mutant EGFR 10 . Clinically significant abnormal 12lead ECG , QT interval correct use Fridericia 's method ( QTCF ) &gt; 450 m 11 . Inability measure QT interval ECG 12 . Personal family history long QT syndrome 13 . Implantable pacemaker implantable cardioverter defibrillator 14 . Resting bradycardia &lt; 55 beats/min 15 . Nonstudy related surgical procedure less equal 7 day prior administration study drug . In case , patient must sufficiently recover stable treatment administration . 16 . Females pregnant breastfeed 17 . Refusal use adequate contraception fertile patient ( female male ) 12 week last dose rociletinib 2 week last dose erlotinib 18 . Presence serious unstable concomitant systemic disorder incompatible clinical study 19 . Any reason investigator considers patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
	<keyword>lung</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>EGFR</keyword>
	<keyword>T790M</keyword>
	<keyword>CO-1686</keyword>
	<keyword>unresectable</keyword>
	<keyword>recurrent</keyword>
	<keyword>EGFR-directed therapy</keyword>
	<keyword>irreversible EGFR inhibitor</keyword>
	<keyword>TIGER</keyword>
	<keyword>rociletinib</keyword>
</DOC>